Price T Rowe Associates Inc Lumos Pharma, Inc. Transaction History

Price T Rowe Associates Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$3.05 - $9.52 $38,356 - $119,723	-12,576 Reduced 11.17%	100,000 $361,000
Q3 2022 Nov 14, 2022	SELL	$7.35 - $9.05 $113,322 - $139,532	-15,418 Reduced 12.05%	112,576 $997,000
Q2 2022 Aug 15, 2022	SELL	$6.68 - $9.39 $211,094 - $296,733	-31,601 Reduced 19.8%	127,994 $986,000
Q2 2021 Aug 16, 2021	BUY	$9.75 - $13.44 $1.56 Million - $2.14 Million	159,595 New	159,595 $1.59 Million

2.2M

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.